McBride S, Walsh D, Meleady P, Daly N, Clynes M
National Cell and Tissue Culture Centre, BioResearch Ireland, Dublin City University, Glasnevin, Ireland.
Differentiation. 1999 Mar;64(3):185-93. doi: 10.1046/j.1432-0436.1999.6430185.x.
Keratin intermediate filaments are formed in epithelial cells in a cell- and tissue-specific manner, but much remains unknown regarding the mechanisms which control the synthesis of these proteins. We examined the effect of the differentiation modulation agent, bromodeoxyuridine (BrdU), on two human keratin-negative (by immunocytochemistry) lung cell lines, DLKP and H82, and showed immunohistochemically that treatment with 10 microM BrdU over 7 days induced K8 and K18 protein synthesis in both lines. Immunoprecipitation and Western blot analyses revealed low levels of K8 and K18 proteins in untreated cell homogenates. These levels increased following treatment with BrdU for 7 days. K8 and K18 mRNAs were detected by Northern blot and reverse transcriptase polymerase chain reaction analyses in both lines before BrdU treatment, but no increase in mRNA levels was observed in either cell line over 21 days of treatment. This suggests, firstly, that keratin synthesis is normally blocked at a posttranscriptional level in DLKP and H82 cells, and secondly, that BrdU can reverse this block. A549 is a human lung cell line which contains K8 and K18 proteins. Treatment with BrdU increased K8 and K18 protein levels in these cells. No corresponding increase in K8 mRNA levels occurred, while an apparent increase in K18 mRNA levels was detected. HL-60 is a leukaemic cell-line of haematopoietic rather than epithelial lineage which contains K8 and K18 mRNA transcripts prior to BrdU treatment, but does not contain keratin proteins. Again, K8 and K18 mRNA levels remained unchanged during BrdU treatment. However, neither K8 nor K18 proteins were detected following treatment, although BrdU is known to alter expression of other genes in HL-60 cells. BrdU thus appears to act at a posttranscriptional level and in an epithelial-specific manner to reverse a block in keratin synthesis in keratin-negative lung cancer cells and increase synthesis in keratin-positive lung cancer cells. This may represent a regulatory step in early lung development or a mechanism whereby tumour cells downregulate expression of a differentiated phenotype.
角蛋白中间丝以细胞和组织特异性的方式在上皮细胞中形成,但关于控制这些蛋白质合成的机制仍有许多未知之处。我们研究了分化调节剂溴脱氧尿苷(BrdU)对两种人角蛋白阴性(免疫细胞化学检测)肺细胞系DLKP和H82的影响,并通过免疫组织化学显示,用10 microM BrdU处理7天可诱导这两种细胞系中K8和K18蛋白的合成。免疫沉淀和蛋白质印迹分析显示,未处理的细胞匀浆中K8和K18蛋白水平较低。用BrdU处理7天后,这些水平升高。在BrdU处理前,通过Northern印迹和逆转录聚合酶链反应分析在两种细胞系中均检测到K8和K18 mRNA,但在21天的处理过程中,两种细胞系中mRNA水平均未升高。这首先表明,在DLKP和H82细胞中,角蛋白合成通常在转录后水平被阻断,其次,BrdU可以逆转这种阻断。A549是人肺细胞系,含有K8和K18蛋白。用BrdU处理可增加这些细胞中K8和K18蛋白水平。K8 mRNA水平没有相应增加,而检测到K18 mRNA水平明显增加。HL-60是一种造血而非上皮谱系的白血病细胞系,在BrdU处理前含有K8和K18 mRNA转录本,但不含有角蛋白。同样,在BrdU处理期间,K8和K18 mRNA水平保持不变。然而,处理后未检测到K8和K18蛋白,尽管已知BrdU会改变HL-60细胞中其他基因的表达。因此,BrdU似乎在转录后水平以上皮特异性方式起作用,以逆转角蛋白阴性肺癌细胞中角蛋白合成的阻断,并增加角蛋白阳性肺癌细胞中的合成。这可能代表了肺早期发育中的一个调节步骤,或者是肿瘤细胞下调分化表型表达的一种机制。